Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com
版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 26,700
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & President | 6.73M | 無 | 1963 |
| Mr. Peter H. Griffith | Executive VP & CFO | 3.07M | 無 | 1959 |
| Mr. Esteban Santos | Executive Vice President of Operations | 3.01M | 無 | 1968 |
| Dr. David M. Reese M.D. | Executive VP & Chief Technology Officer | 3.4M | 無 | 1963 |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | 3.24M | 無 | 1967 |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance | 無 | 無 | 1974 |
| Mr. Mike Zahigian | Senior VP & Chief Information Officer | 無 | 無 | 無 |
| Dr. James E. Bradner M.D. | Executive VP of Research and Development & Chief Scientific Officer | 無 | 無 | 1972 |
| Justin G. Claeys | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Jonathan P. Graham | Executive VP, General Counsel & Secretary | 2.44M | 無 | 1961 |
描述
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
公司管治
截至 2024年4月1日 止，Amgen Inc. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：2；董事會：8；股東權利：1；現金賠償：2。
